TRANSGENE (EPA:TNG) | WebDisclosure

PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 2 months ago

Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique de son vaccin individualisé contre le cancer ? Perspectives prometteuses pour 2025
Transgene publie ses résultats annuels 2024 et fait le point sur son activité, notamment la preuve de principe clinique de son vaccin individualisé contre le cancer. Perspectives prometteuses pour 2025

Résultats Annuels Perspectives Cancer Transgene Vaccin Thérapeutique
PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 2 months ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 1 year 5 months ago

Transgene se prépare pour le Biomed Forum des investisseurs

Investisseurs BIOMED Forum Immunothérapie Transgene Vecteurs Viraux
BRIEF

published on 01/21/2025 at 17:50, 1 year 5 months ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 5 months ago

Transgene participera à la conférence investisseurs Biomed Forum
Transgene participera à la conférence investisseurs Biomed Forum le 4 février 2025. Présentation de ses immunothérapies contre le cancer reposant sur des vecteurs viraux

BIOMED Forum Immunothérapie Cancer Transgene Vecteurs Viraux
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 5 months ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 1 year 7 months ago

Transgene et ProBioGen unissent leurs forces pour les vaccins anti-cancer personnalisés

Biotechnologie Cancer Transgene ProBioGen Vaccins Personnalisés
BRIEF

published on 11/05/2024 at 07:35, 1 year 7 months ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
PRESS RELEASE

published on 11/05/2024 at 07:30, 1 year 7 months ago

Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés
Transgene et ProBioGen collaborent pour développer les vaccins thérapeutiques individualisés, annoncent un accord de licence pour la lignée cellulaire AGE1.CR.pIX®

Transgene Vaccins ProBioGen Thérapeutiques Lignée Cellulaire
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 8 months ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Published on 06/25/2026 at 23:30, 2 hours 7 minutes ago

Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 3 hours 7 minutes ago

Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 4 hours 5 minutes ago

BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 10 hours 7 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/25/2026 at 15:00, 10 hours 37 minutes ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

View all ACCESSWIRE

Published on 06/25/2026 at 22:40, 2 hours 56 minutes ago

DeFi Technologies Inc. Announces Extension of Proxy Voting Deadline for Upcoming Annual General and Special Meeting
Published on 06/25/2026 at 19:00, 6 hours 36 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA resolves to prepare for the transition from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange
Published on 06/25/2026 at 18:59, 6 hours 37 minutes ago

OHB Digital Connect completes upgrade of military ground stations
Published on 06/25/2026 at 18:40, 6 hours 56 minutes ago

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias
Published on 06/25/2026 at 18:30, 7 hours 6 minutes ago

Delisting of Northern Data AG Shares - Munich Stock Exchange Decides on the Timeline

View all EQS

Published on 06/25/2026 at 18:45, 6 hours 51 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 7 hours 7 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 7 hours 47 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 06/25/2026 at 17:50, 7 hours 47 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 06/25/2026 at 15:58, 9 hours 38 minutes ago

260625 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE

News